Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Disease control rate (DCR)

number of patients with complete response, partial response or stable disease according to RECIST

Time frame: From start of treatment of the first subject until 3 years later, assessed every 6 weeks

Overall survival (OS)

time (days) from date of first treatment to death due to any cause.

Time frame: From start of treatment of the first subject until 3 years later

Time to progression (TTP)

time (days) from date of first treatment to first observed radiological disease progression

Time frame: From start of treatment of the first subject until 3 years later, assessed every 6 weeks

Progression-free survival (PFS)

time (days) from date of first treatment to first observed radiological disease progression or death

Time frame: From start of treatment of the first subject until 3 years later, assessed every 6 weeks

Duration of response (DOR)

time (days) from date of first radiological response to the date that progressive disease is first radiologically documented or death occurs

Time frame: From start of treatment of the first subject until 3 years later, assessed every 6 weeks

Stable disease (SD)

time (days) from date of first treatment to first observed radiological disease progression or death

Time frame: From start of treatment of the first subject until 3 years later, assessed every 6 weeks